Thrombotargets Corp announced today that it has submitted its Orphan Drug Application of TT-103MH to the FDA for bleeding treatment in von Willebrand patients

July 19th 2007: Thrombotargets Corporation announced today that it has submitted its Orphan Drug Application of its Human Recombinant protein known as TT-103MH to the United States Food and Drug Administration (FDA) for bleeding treatment in von Willebrand patients “ We are extremely proud and remain very optimistic that the FDA will look favorably on this designation, said Dr. Pedreño Thrombotargets President and CEO, “We remain very optimistic given the early Laboratory results, that demonstrate that TT-103MH is a viable and a very efficacious alternative to current replacement therapy in hereditary coagulation disorders as von Willebrand diseases and considering previous TT-103MH Orphan Drug Designation for the treatment of Hemophiliacs ” said Dr. Pedreño president and CEO.

The FDA grants orphan drug status for drug candidates that are intended to treat rare life-threatening diseases that, at the time of application, affect no more than 200,000 patients in the United States. The drug must have the ability to provide significant patient benefit over currently available treatment or fill an unmet medical need. Orphan drug designation entitles Thrombotargets corp. to seven years of market exclusivity in the United States upon FDA approval, provided that Thrombotargets Corp. continues to

ABOUT THROMBOTARGETS GROUP
Thrombotargets group is comprised by three companies; Thrombotargets Corporation (Durham, NC, USA) is responsible for Drug Development and Business Development; Thrombotargets Europe (Barcelona, Spain) for Target Identification, Lead validation and Lead optimization and Biotech Libraries (Spain) for engineered targeted libraries and High Throughput Screening.

Thrombotargets has developed and adapted to High Throughput Screening, a new family of biological assays, Hemosta-BIOPLATFORMSCREEN™, capable to quantify simultaneously clot formation and clot lysis , Oxidant- BIOPLATFORMSCREEN™ to quantify total antioxidant capacity and Athero- BIOPLATFORMSCREEN™, to quantify low-density lipoprotein modification. With these proven proprietary new HTS Platforms (BIOPLATFORMSCREEN™), Thrombotargets group is creating a continuously novel and promising pipeline of drug candidates. TT-103MH, Thrombotargets’ most advanced drug candidate, has recently been granted with an Orphan Drug Designation.

Contact:
Luis Caveda Ph.D.
Thrombotargets Corp.
COO
luiscaveda@thrombotargets.com